Update on the pathogenesis and treatment of the antiphospholipid syndrome

Current Opinion in Rheumatology

Volumn 27, Issue 5, 2015, Pages 476-482

  Chighizola, Cecilia Beatrice ^a,b   Raschi, Elena ^a   Borghi, M Orietta ^a,b   Meroni, Pier Luigi ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

Antiphospholipid antibodies; Antiphospholipid syndrome; Pathogenesis; Treatment

Indexed keywords

ANTIVITAMIN K; BETA2 GLYCOPROTEIN 1; BETA2 GLYCOPROTEIN 1 ANTIBODY; CELL RECEPTOR; ECULIZUMAB; PHOSPHOLIPID ANTIBODY; RITUXIMAB;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; BIOLOGICAL ACTIVITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; NONHUMAN; PATHOGENESIS; PREGNANCY COMPLICATION; PREGNANT WOMAN; PRIORITY JOURNAL; REVIEW; AUTOIMMUNITY; IMMUNOLOGY;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNITY; HUMANS;

EID: 84942581213     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000200     Document Type: Review

References (42)

1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4:295-306.
2. Bertolaccini ML, Amengual O, Andreoli L, et al. 14th International Congress on antiphospholipid antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev 2014; 13:917-930. This study from the latest International Task Force discusses available evidence on the laboratory assays to detect antiphospholipid antibodies, focusing on both criteria and novel tests.
3. Abreu MM, Danowski A, Wahl DG, et al. The relevance of ' noncriteria' clinical manifestations of antiphospholipid syndrome: 14th International Congress on antiphospholipid antibodies T echnical Task Force Report on antiphospholipid syndrome clinical features. Autoimmun Rev 2015; 14:401-414. This study from the latest International Task Force offers an update on the manifestations that are increasingly recognized as part of the clinical spectrum of APS, but are still not included in the classification criteria.
4. Chighizola CB, Gerosa M, Meroni PL. New tests to detect antiphospholipid antibodies: antidomain I beta-2-glycoprotein-I antibodies. Curr Rheumatol Rep 2014; 16:402-409. 5.
5. Agostinis C, Durigutto P, Sblattero D, et al. A noncomplement-fixing antibody to b2 glycoprotein I as a novel therapy for antiphospholipid syndrome. Blood 201 4; 123:3478-3487. This in-vivo study further highlights the pathogenicity of antibodies targeting domain I of b2GPI. In addition, a monoclonal antibody against domain I not able to activate complement is presented for the first time as a potential th erapeutic tool in thrombotic and obstetric manifestations. 6.
6. Zandman-Goddard G, Pierangeli SS, Gertel S, Blank M. Tolerogenic dendritic cells specific for b2-glycoprotein-I Domain-I, attenuate experimental antiphosphol ipid syndrome. J Autoimmun 2014; 54:72-80. Tolerogenic dendritic cells specific for domain I of b2GPI are suggested as a novel therapeutic approach for APS. 7.
7. Pengo V, Ruffatti A, Tonello M, et al. Antiphospholipid syndrome: antibodies to domain 1 of b2-glycoprotein 1 correctly classify patients at risk. J Thromb Haemost 2015. doi: 10.1111/jth.12865. In this study, positivity for anti-domain I antibodies consistently confirmed at 12 we eks identifies patients at highest risk of developing thromboembolic events.
8. Andreoli L, Chighizola CB, Nalli C, et al. Antiphospholipid antibody profiling: the detection of IgG antibodies against b2glycoprotein I domain 1 and 4/5 offers better clinical characterization. Arthritis Rheumatol 2015. doi: 10.1002/art.39187 (in press).
9. Artenjak A, Locatelli I, Brelih H, et al. Immunoreactivity and avidity of IgG a ntib2-glycoprotein I antibodies from patients with autoimmune diseases to different peptide clusters of b2-glycoprotein I. Immunol Res 2015; 61:35-44.
10. Meroni PL, Chighizola CB, Rovelli F, Gerosa M. Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers. Arthritis Res Ther 2014; 209:1-14.
11. Raschi E, Chighizola CB, Grossi C, et al. b 2-glycoprotein I, lipopolysaccharide and endothelial TLR4: Three players in the two hit theory for antiphospholipid-mediated thrombosis. J Autoimmun 2014; 55:42-50. This in-vitro study provides novel insights into TLR4 engagement by b2GPI; noteworthy, this interaction appears not to be LPS-dependent in endothelial cells.
12. Benhamou Y, Bellien J, Armengol G, et al. Role of Toll-like Receptors 2 and 4 in mediating endothelial dysfunction and arte rial remodeling in primary arterial antiphospholipid syndrome. Arthritis Rheumatol 2014; 66:3210-3220.
13. Brandt KJ, Fickentscher C, Boehlen F, et al. NF-kB is activated from endosomal compartm ents in antiphospholipid antibodies-treated human monocytes. J Thromb Haemost 2014; 12:779-791.
14. Laplante P, Amireault P, Subang R, et al. Interaction of b2-glycoprotein I with lipopolysaccha ride leads to Toll-like receptor 4 (TLR4)-dependent activation of macrophages. J Biol Chem 2011; 286:42494-42503.
15. Ruff WE, Vieira SM, Kriegel MA. The Role of the gut microbiota in the pathogenesis of antiphospholipid syndrome. Curr Rheumatol Rep 2015; 472:1-10.
16. Nishimura M, Nii T, Trimova G, et al. The NF-kB specific inhibitor DHMEQ prevents thrombus formation in a mouse model of antiphospholipid syndrome. J Nephropathol 2013; 2:114-121.
17. Lambrianides A, Carroll CJ, Pierangeli SS, et al. Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signaling pathways. J Immunol 2010; 184:6 622-6628.
18. Poulton K, Ripoll VM, Pericleous C, et al. Purified IgG from patients with obstetric but not IgG from nonobstetric antiphospholipid syndrome inhibit trophoblast invasion. Am J Reprod Immunol 2014; 73:390-401. This study suggests that antibodies purified from patients with thrombotic versus pure obstetric clinical manifestations may elicit different in-vitro biological effects in trophoblast cells.
19. Can aud G, Bienaimé F, Tabarin F, et al. Inhibition of the mTORC pathway in the antiphospholipid syndrome. N Engl J Med 2014; 371:303-312. The in-vitro and in-vivo experiments presented in this study support the involve ment of mTOR pathway in the APS, proposing sirolimus-A mTOR inhibitor-As a potential pharmacological tool in patients undergoing renal transplantation.
20. Van Laecke S, Nagler EV, Vanholder R. Inhibition of the mTORC Pathway in the antiphospholipid syndrome. N Engl J Med 2014; 371:1553.
21. Romay-Penabad Z,Carrera Marin A,Willis R,et al. Complement C5-inhibitor rEV576 (coversin) ameliorates in-vivo effects o f antiphospholipid antibodies Lupus, 2014, 23, 1324-1326.
22. Chighizola CB, Moia M, Meroni PL. New oral anticoagulants in thrombotic antiphospholipid syndrome. Lupus 2014; 23:1279-1282.
23. Son M, Wypasek E, Celinska-Lowenhoff M, Undas A. The use of rivaroxaban in patients with antiphospholipid syndrome: a series of 12 cases. Thromb Res 2015; 135:1035-1036.
24. Schaefer JK, McBane RD, Black DF, et al. Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients. Thromb Haemost 2014; 112:947-950. 25.
25. Erkan D, Aguiar CL, Andrade D, et al. 14th International Congress on Antiphospholipid Antibodies Task Force Report on antiphospholipid syndrome treatment trends. Autoimmun Rev 2014; 13:685-696. This report from the latest International Task Force extensively reviews all the therapeutic options-from the established to the cutting edge ones-that might be considered in the management of patients with antiphospholipid antibodies.
26. Kronbichler A, Frank R, Kirschfink M, et al. Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome. Medicine (Baltimore) 2014; 93:e143.
27. Lonze BE, Zachary AA, Magro CM, et al. Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation. Am J Transplant 2014; 14:459-465.
28. Alij otas-Reig J, Ferrer-Oliveras R, Ruffatti A, et al. The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): a survey of 247 consecutive cases. Autoimmun Rev 2015; 14:387-395.
29. Chighizola CB, Gerosa M, Trespidi L, et al. Update on the current recommendations and outcomes in pregnant women with antiphospholipid syndrome. Expert Rev Clin Immunol 2014; 10:1505-1517. This recent review covers the everyday therapeutic approaches to pregnant women with antiphospholipid antibodies.
30. Bouvier S, Cochery-Nouvellon E, Lavigne-Lissalde G, et al. Comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the NOH-APS observational study. Blood 2014; 123:404-413.
31. Ruffatti A, Salvan E, Del Ross T, et al. Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. Thromb Haemost 2014; 1 12: 727-735. This retrospective cohort study identifies additional treatments as the only predictor of favourable pregnancy outcome among women with triple antiphospholipid antibody-positivity and a history of thrombosis.
32. Watanabe N, Yamaguchi K, Motomura K, et al. Combination therapy with anticoagulants, corticosteroids and intravenous immunoglobulin for women with severe obstetric antiphospholipid syndrome. Clin Exp Rheumatol 2014; 32:299-3 00. This case series supports the efficacy of intravenous immunoglobulins on top of standard treatment in the therapeutic management of women with refractory obstetric APS.
33. Mekinian A, Lazzaroni MG, Kuzenko A, et al. The efficacy of hydroxychloroquine for obstetrical outcome in antiphospholipid syndrome: data from a European multicenter retrospective study. Autoimmun Rev 2015; 1-5. This multi-centre retrospective study proposes HCQ as a novel eff ective tool in the management of refractory obstetric APS.
34. Marchetti T, Ruffatti A, Wuillemin C, et al. Hydroxychloroquine restores trophoblast fusion affected by antiphospholipid antibodies. J Thromb Haemost 2014; 12:910-920.
35. Albert CR, Schlesinger WJ, Viall CA, et al. Effect of hydroxychloroquine on antiphospholipid antibody-induced changes in first trimester trophoblast function. Am J Reprod Immunol 2013; 71:154-164.
36. Ota K, Dambaeva S, Han AR, et al. Vitamin D deficiency may be a risk factor for recurrent pregnancy losses by increasing cellular immunity and autoimmunity. Hum Reprod 2014; 29:208-219. 37.
37. Gysler SM, Mulla MJ, Stuhlman M, et al. Vitamin D reverses aPL-induced inflammation and LMWH-induced sFlt-1 release by human trophoblast. Am J Reprod Immunol 2014; 73:242-250. This in-vitro study shows that vitamin D treatment attenuates the inflammatory response induced by antiphospholipid antibodies in trophoblast cells.
38. Arnaud L, Mathian A, Devilliers H, et al. Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. Autoimmun Rev 2015; 14:192-200. According to this recent meta-Analysis, low-dose aspirin exerts a protective antithrombotic effect among asymptomatic antiphospholipid antibody patients and women with obstetric APS.
39. Erkan D, Willis R, Murthy VL, et al. A prospective open-label pilot s tudy of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients. Ann Rheum Dis 2014; 73:1176-1180. This ex-vivo study reports the reduction of the serum levels of several proinflamma tory and pro-thrombotic parameters by fluvastatin.
40. Mattia E, Ruffatti A, Tonello M, et al. IgA anticardiolipin and IgA antib2 glycoprotein I antibody positivity determined by fluorescence enzyme immunoassay in pri mary antiphospholipid syndrome. Clin Chem Lab Med 2014; 52:1329-1333.
41. Ruiz-Garcá R, Serrano M, Martínez-Flores JÁ, et al. Isolated IgA anti b2 glycoprotein I antibodies in patients with clinical criteri a for antiphospholipid syndrome. J Immunol Res 2014. doi: 10.1155/2014/704395.
42. Cousins L, Pericleous C, Khamashta M, et al. Antibodies to domain I of b-2-glycoprotein I and IgA antiphospholipid antibodies in patients with 'seronegative ' antiphospholipid syndrome. Ann Rheum Dis 2015; 74:317-319.